Sector News

Alexion appoints new senior VP for EMEAC region

February 6, 2018
Life sciences

Camillia HartvigAlexion Pharma has appointed Camilla Harder Hartvig as its senior vice president and head of its EMEAC region.

She will lead the commercial activities of the regional function from Alexion’s EMEAC headquarters in Zurich, Switzerland, where she will succeed Christophe Bourdon who recently left the company to pursue a new opportunity.

Regarding her new role, Hartvig said: “I am delighted to join the great team in this region, that is a strategic pillar for Alexion accounting for more than a third of Alexion’s global business, and look forward to stewarding the company’s growth and development hire in the years ahead.”

Hartvig, who has more than 20 years’ experience in the pharmaceutical industry, has worked in a broad spectrum of companies, including AstraZeneca, Novartis and Allergan.

Her expertise lies in a range of therapeutic areas such as cardiovascular, diabetes, respiratory, ophthalmology and oncology.

She was most recently president, international markets at Glenmark Pharmaceuticals, where she led the commercial organisation across the European, Russian, Asian and Latin American regions.

Source: PMLive

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.